ZEB2 and neoplasm: Importantly, silencing of ZEB2 suppresses activation of this mechanism by anti-angiogenic agents, highlighting the HIF-1α–ZEB2–ephrinB2 signalling axis as a potential target for countering tumour cell invasion and overcoming resistance against anti-angiogenic therapies.